Skip to content
Menu

HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.

HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.

Read at benzinga.com

← All stock news